Forest Ray PhD,  —

Articles by

New CTSD Gene Variant Not Linked to Rare CLN10 Batten in Case

A new mutation found in the CTSD gene does not associate with the rare CLN10 form of Batten disease, despite occurring in a girl in China with CLN10-like symptoms, according to the results of a recent case report. Nonetheless, the discovery of this new mutation “has significance” and will…

Twins’ Different Symptoms Complicate Diagnosis

Juvenile Batten disease is difficult to diagnose promptly and accurately, as demonstrated by the case of twin girls with different symptoms of the same disorder. The case suggests that a referral to a specialist should be made when a patient’s clinical picture doesn’t line up with their history, or…

EMA Names Potential Gene Therapy for CLN5 Batten an Orphan Drug

The European Medicines Agency (EMA) designated Neurogene’s gene therapy candidate for CLN5, a form of late-infantile Batten disease, an orphan drug as a potential treatment of the disorder. “This regulatory designation is an important milestone toward addressing the urgent, unmet need of families and patients living with CLN5, and…

Updates Delayed on Regenxbio’s CLN2 Gene Therapy Programs

Regenxbio plans to provide updates on its RGX-181 and RGX-381 gene therapy candidates for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease, in the second half of this year. The company is currently reviewing information requests from…